Clinical Trials Browser

Ependymoma × Bevacizumab × 1 year × Clear all

NCT01356290 2026-02-23

MEMMAT

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Phase 2 Active not recruiting

Ependymoma, Medulloblastoma

NCT01295944 2025-08-05

Carboplatin and Bevacizumab for Recurrent Ependymoma

Phase 2 Completed

35 enrolled 17 charts

Brain Neoplasms, Ependymoma, Neoplasms, Neurologic Manifestations, Spinal Cord Neoplasms